Leukemia (Treatment)

Interleukin-2-Activated Stem Cells Used To Treat Leukemia, Lymphoma

Published in Blood Weekly, October 11th, 1999

A recent study presented results of treating poor-prognosis leukemia and lymphoma patients with interleukin-2-activated bone marrow and stem cells.

K.A. Margolin and colleagues, City of Hope National Medical Center, California, conducted a pilot trial of interleukin (IL)-2-treated autologous bone marrow (BM) and peripheral stem cell (PSC)-supported high-dose chemoradiotherapy ("Interleukin-2-Activated Autologous Bone Marrow and Peripheral Blood Stem Cells in the Treatment of Acute Leukemia and Lymphoma," Biol Blood Marrow Transplant 1999;5(1):36-45).

They reported on 36 patients with poor-prognosis leukemia and lymphoma who received BM and/or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry